Global Neurology Academy

The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.

For more information about GNA, visit www.globalneurologyacademy.org.

397

LikeLikedUnlike

1-15 of 206

Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiers
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Rethinking Progression in Multiple Sclerosis
NeuroFrontiers
Rethinking Progression in Multiple Sclerosis
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Christopher Lock, MD
  Peer
The Burden of Cognitive Dysfunction in Multiple Sclerosis
NeuroFrontiers
The Burden of Cognitive Dysfunction in Multiple Sclerosis
- Christopher Lock, MD
  Peer
Strategies to Safeguard Brain Health in MS
NeuroFrontiers
Strategies to Safeguard Brain Health in MS
- Christopher Lock, MD
  Peer
Switching to Risdiplam Maintains Motor Gains in SMA Patients
AudioAbstracts
Switching to Risdiplam Maintains Motor Gains in SMA Patients
- Ryan Quigley
  Peer
Who’s Missing from Multiple Sclerosis Research?
NeuroFrontiers
Who’s Missing from Multiple Sclerosis Research?
- Ashley Baker, MSN, PMHNP
  Peer
- Ruth Ann Marrie, MD, PhD
  Peer
advertisement
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiers
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiers
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
Multiple Sclerosis Without Borders: Taking a Global View
NeuroFrontiers
Multiple Sclerosis Without Borders: Taking a Global View
- Andrew Wilner, MD, FACP, FAAN
  Peer
- Victor Rivera, MD
  Peer
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
NeuroFrontiers
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
- Raphael Schneider, MD, PhD, FRCPC, CIP
  Peer
Understanding Accelerated Biological Aging in Pediatric MS
NeuroFrontiers
Understanding Accelerated Biological Aging in Pediatric MS
- Jennifer Yang, MD
  Peer
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
NeuroFrontiers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
- Adil Harroud, MD
  Peer
- Dylan Hamitouche
  Peer
- Ryan Quigley
  Peer
advertisement
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
- Mike Sharma, MD, MSc, FRCPC
  Peer
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
- Ashkan Shoamanesh, MD
  Peer
Evaluating Structured Interventions for Cognitive Support in MS
AudioAbstracts
Evaluating Structured Interventions for Cognitive Support in MS
- Hallie Blevins, PhD
  Peer